Commentary

Podcast

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.

This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.

Related Videos
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
Pharmacy technician working in a pharmacy -- Image credit: sofiko14 | stock.adobe.com
Team of pharmacists -- Image credit: Jacob Lund | stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
Related Content
Close-up of tumor in lungs -- Image credit: Dr_Microbe | stock.adobe.com
October 23rd 2024

Current Targeted Therapy Options in ROS1-Positive NSCLC

Nicole Bentivegna, PharmD, BCOP
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Team of health care professionals -- Image credit: New Africa | stock.adobe.com
October 23rd 2024

The Pharmacist’s Role on the Multiple Myeloma Care Team Can Vary Among Cancer Centers When Treating Patients With Bispecifics

Gillian McGovern, Assistant Editor
Public Health Matters podcast logo
September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

Cancer cells, 3D illustration
October 22nd 2024

Mycosis Fungoides and Sézary Syndrome, Subtypes of Cutaneous T-Cell Lymphoma, Compromise Health-Related Quality of Life in Patients

Luke Halpern, Assistant Editor
Solid tumor -- Image credit: Yuriy | stock.adobe.com
October 22nd 2024

Introducing Tarlatamab-dlle: A New Era in Oncology Treatment

Amir Ali, PharmD, BCOP Phoebe Kim, PharmD Candidate Stacey Cheung, PharmD Candidate Samantha Shi, PharmD, BCOP Harry Shamamian, PharmD, MBA, FACHE Hien Tang, PharmD, BCOP